Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Sell
31
ZVRA Quote, Financials, Valuation and Earnings
Last price:
$7.84
Seasonality move
:
-6.77%
Day range:
$7.77 - $7.99
52-week range:
$4.20 - $9.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.37x
P/B ratio:
10.71x
Volume:
211.5K
Avg. volume:
454.2K
1-year change:
35.34%
Market cap:
$424.8M
Revenue:
$23.6M
EPS (TTM):
-$2.26
Analysts' Opinion
-
Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.63, Zevra Therapeutics has an estimated upside of 175.48% from its current price of $7.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $7.85.
Fair Value
-
According to the consensus of 4 analysts, Zevra Therapeutics has 175.48% upside to fair value with a price target of $21.63 per share.
ZVRA vs. S&P 500
-
Over the past 5 trading days, Zevra Therapeutics has underperformed the S&P 500 by -0.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Zevra Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zevra Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Zevra Therapeutics reported revenues of $12M.
Earnings Growth
-
Zevra Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zevra Therapeutics reported earnings per share of -$0.69.
Enterprise value:
414.8M
EV / Invested capital:
--
Price / LTM sales:
15.37x
EV / EBIT:
--
EV / Revenue:
17.57x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-5.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$16.2M
Return On Assets:
-62.98%
Net Income Margin (TTM):
-446.85%
Return On Equity:
-208.85%
Return On Invested Capital:
-102.42%
Operating Margin:
-128.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $10.2M | $27.5M | $23.6M | $12.9M | $12M | |
| Gross Profit | $9.9M | $25.3M | $16.2M | $11.7M | $10.7M | |
| Operating Income | -$42.6M | -$49.6M | -$87M | -$15.2M | -$15.4M | |
| EBITDA | -$25.5M | -$43.5M | -$76.4M | -$18.3M | -$16.5M | |
| Diluted EPS | -$0.78 | -$1.30 | -$2.26 | -$0.54 | -$0.69 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.4M | $115.1M | $92.8M | $86.9M | $86M | |
| Total Assets | $11.2M | $132.9M | $115.3M | $172.3M | $178.1M | |
| Current Liabilities | $7.5M | $4.2M | $12M | $73.7M | $34.1M | |
| Total Liabilities | $77.6M | $5.8M | $40.2M | $110.5M | $138.5M | |
| Total Equity | -$66.4M | $127.1M | $75.1M | $61.9M | $39.7M | |
| Total Debt | $68.4M | -- | $12.8M | $42.8M | $59.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.7M | -$33.5M | -$69.7M | -$16.2M | -$16.3M | |
| Cash From Investing | -$36.7M | -$17.4M | -$22.2M | $10.6M | -$5.5M | |
| Cash From Financing | $8.4M | $28.5M | $82.1M | $5M | $796K | |
| Free Cash Flow | -$18.8M | -$33.8M | -$69.7M | -$16.2M | -$16.3M | |
ZVRA
Sector
Market Cap
$424.8M
$36.5M
Price % of 52-Week High
80.43%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
-15.11%
-0.9%
1-Year Price Total Return
35.35%
-39.9%
Beta (5-Year)
1.977
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.00
200-day SMA
Buy
Level
$7.52
Bollinger Bands (100)
Sell
Level
7.79 - 8.85
Chaikin Money Flow
Sell
Level
-112.2M
20-day SMA
Sell
Level
$7.96
Relative Strength Index (RSI14)
Sell
Level
47.40
ADX Line
Sell
Level
7.47
Williams %R
Neutral
Level
-54.7009
50-day SMA
Sell
Level
$7.90
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
44.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0828)
Sell
CA Score
(Annual)
Level (-3.5083)
Buy
Beneish M-Score
(Annual)
Level (-3.8764)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.8932)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Stock Forecast FAQ
In the current month, ZVRA has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZVRA average analyst price target in the past 3 months is $21.63.
-
Where Will Zevra Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zevra Therapeutics share price will rise to $21.63 per share over the next 12 months.
-
What Do Analysts Say About Zevra Therapeutics?
Analysts are divided on their view about Zevra Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zevra Therapeutics is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Zevra Therapeutics's Price Target?
The price target for Zevra Therapeutics over the next 1-year time period is forecast to be $21.63 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZVRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zevra Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZVRA?
You can purchase shares of Zevra Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zevra Therapeutics shares.
-
What Is The Zevra Therapeutics Share Price Today?
Zevra Therapeutics was last trading at $7.84 per share. This represents the most recent stock quote for Zevra Therapeutics. Yesterday, Zevra Therapeutics closed at $7.85 per share.
-
How To Buy Zevra Therapeutics Stock Online?
In order to purchase Zevra Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
